DiagnoCure licenses next-gen uPM3 to Gen-Probe
This article was originally published in The Gray Sheet
Executive Summary
Co-development pact for urine-based prostate cancer diagnostic, focusing on the PCA3 (DD3) genetic marker, corresponds with Gen-Probe's plan to broaden nucleic acid test offerings, CEO Henry Nordhoff says in Nov. 20 release. Gen-Probe will pay $3 mil. upfront to DiagnoCure, plus additional payments of up to $7.5 mil. DiagnoCure also will collect royalties of 8% on net product sales of up to $5 mil., and royalties of 16% on sales above $50 mil. "The test may offer advantages over prostate specific antigen (PSA) testing," the release notes...